Shao and co-workers developed polyamidoamine-aptamer-coated hollow MSNs to deliver the drug sorafenib and CRISPR/Cas9 to target epidermal growth factor receptor (EGFR) to, thus, enhance hepatocellular carcinoma C treatment [27]. Here, EGFR is linked to hepatocellular carcinoma.